Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00686075 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants
A Phase 1 study, sponsored by MedImmune.
- Completed
- Registry status
- Phase 1
- Development phase
- 1,338
- Enrollment target
NCT00686075 is a Phase 1 study that has completed, run by MedImmune. The registered enrollment target is 1,338 participants.
The verdict
NCT00686075, a Phase 1 study, has completed, sponsored by MedImmune.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1,338 participants
- Enrollment target
Study Summary
Primary objective of this study is to describe the safety and tolerability of multiple doses of MEDI-534 in children 6 to less than (\<) 24 months of age and in infants 2 months of age.
Interventions
- BIOLOGICAL MEDI-534, Cohort 1
- OTHER Placebo, Cohort 1
- BIOLOGICAL MEDI-534, Cohort 2
- OTHER Placebo, Cohort 2
- BIOLOGICAL MEDI-534, Cohort 3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,338 participants |
| Start Date | 2008-06 |
| Est. Completion | 2012-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00686075
The ClinicalTrials.gov registry entry for NCT00686075 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1,338 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MEDI-534, Cohort 1 is the first listed.
NCT00686075 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00686075 about?
NCT00686075 is a clinical study titled "A Study to Evaluate the Safety, Tolerability, Immunogenicity and Vaccine-like Viral Shedding of MEDI-534, Against Respiratory Syncytial Virus (RSV) and Parainfluenza Virus Type 3 (PIV3), in Healthy 6 to <24 Month-old Children and in 2 Month-old Infants". Primary objective of this study is to describe the safety and tolerability of multiple doses of MEDI-534 in children 6 to less than (\<) 24 months of age and in infants 2 months of age.
What is the current status of trial NCT00686075?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1,338 participants. The study started on 2008-06. Estimated completion is 2012-08.
What interventions are being tested in trial NCT00686075?
The interventions under investigation include: MEDI-534, Cohort 1 (BIOLOGICAL), Placebo, Cohort 1 (OTHER), MEDI-534, Cohort 2 (BIOLOGICAL), Placebo, Cohort 2 (OTHER), MEDI-534, Cohort 3 (BIOLOGICAL).
Who is sponsoring clinical trial NCT00686075?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.